MediPharm Labs (MediPharm Labs) Debt-to-EBITDA : -0.20 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is MediPharm Labs Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

MediPharm Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.52 Mil. MediPharm Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.04 Mil. MediPharm Labs's annualized EBITDA for the quarter that ended in Mar. 2024 was $-8.01 Mil. MediPharm Labs's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.20.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for MediPharm Labs's Debt-to-EBITDA or its related term are showing as below:

MEDIF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.35 Med: -0.02 Max: 1.09
Current: -0.2

During the past 7 years, the highest Debt-to-EBITDA Ratio of MediPharm Labs was 1.09. The lowest was -0.35. And the median was -0.02.

MEDIF's Debt-to-EBITDA is ranked worse than
100% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.68 vs MEDIF: -0.20

MediPharm Labs Debt-to-EBITDA Historical Data

The historical data trend for MediPharm Labs's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediPharm Labs Debt-to-EBITDA Chart

MediPharm Labs Annual Data

Trend

Sep17

Sep18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

1.09

-0.35

-0.01

-0.02

-0.22

MediPharm Labs Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.02	-0.38	-0.19	-0.24	-0.20

Competitive Comparison of MediPharm Labs's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, MediPharm Labs's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MediPharm Labs's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MediPharm Labs's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where MediPharm Labs's Debt-to-EBITDA falls into.

MediPharm Labs Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

MediPharm Labs's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.659	+	0.051)	/	-7.81
	=	-0.22

MediPharm Labs's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.52	+	0.043)	/	-8.012
	=	-0.20

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.

MediPharm Labs (OTCPK:MEDIF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

MediPharm Labs Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of MediPharm Labs's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

MediPharm Labs (MediPharm Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MediPharm Labs Corp (OTCPK:MEDIF) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

MLZ:Germany LABS:Canada

Address

151 John Street, Barrie, ON, CAN, L4N 2L1

Website

https://www.medipharmlabs.com

MediPharm Labs Corp is a pharmaceutical company specializing in precision-based cannabinoids. The Company operates in one reportable segment, the production and sales of cannabis extracts and derivative products. Through its wholesale and white-label platforms, MediPharm Labs formulates, develops, processes, packages, and distributes cannabis extracts and cannabinoid-based products to domestic and international markets. Geographically company has a presence in Canada, Australia, Germany, and other countries and the majority of revenue derives from Canada.